Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

lysosomal storage disease

13th Mar 2025

Plain language summary of the ASCEND-Peds study: Two-year results of olipudase alfa treatment in children with acid sphingomyelinase deficiency (ASMD)

23rd Sep 2024

Plain language summary of the ASCEND study on one-year treatment outcomes with olipudase alfa in adults with acid sphingomyelinase deficiency (ASMD)

Mucopolysaccharidosis type I (MPS I) is a rare genetic condition, resulting from disease-causing changes in the IDUA gene called pathogenic variants. There are two different types of variants: • Null variants – cells cannot make the alpha-L-iduronidase enzyme • Missense variants – cells make a partly functional or severely reduced amount of the fully functional enzymeThe alpha-L-iduronidase enzyme breaks down large sugar molecules called glycosaminoglycans (GAGs). In people with MPS I, the enzyme is unable to break down GAGs and they build up in cells.Based on the severity of the condition, doctors categorise MPS I into two types, called phenotypes:• Attenuated MPS I • Severe MPS ITreatment options differ depending on MPS I phenotype. There are currently no tests that accurately determine MPS I phenotype. Using information from the MPS I Registry, researchers wanted to find out whether knowing the specific combination of the 2 disease-causing gene variants (genotype) can help predict whether a person has an attenuated or severe phenotype
17th Jan 2024

Looking at whether genetic testing can help doctors diagnose the severity of MPS I- a plain language summary

25th Nov 2022

Plain language summary of a study looking at the age at diagnosis and time to start of treatment in individuals with mucopolysaccharidosis type I (MPS I)

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy